Portfolio Company Aura Biosciences Announces Closing of USD99 million Public Offering of Common Stock (1770215)

Arix Bioscience PLC (ARIX) 
Portfolio Company Aura Biosciences Announces Closing of USD99 million Public Offering of Common Stock 
10-Nov-2023 / 08:00 GMT/BST 
=---------------------------------------------------------------------------------------------------------------------- 
 
Arix Bioscience plc 
 
Portfolio Company Aura Biosciences Announces Closing of USD99 million Public Offering of Common Stock 
 
LONDON, 10 November 2023: Arix Bioscience plc ("Arix" or the "Company") (LSE: ARIX), a transatlantic venture capital 
company focused on investing in breakthrough biotechnology companies, notes that its Core Portfolio company, Aura 
Biosciences (NASDAQ: AURA) ("Aura"), has announced the closing of its underwritten public offering of 11,000,000 shares 
of its common stock at a price to the public of USD9.00 per share. 
 
The Company received net proceeds from the Offering, after deducting the underwriting discounts and commissions and 
estimated offering expenses payable by the Company, of approximately USD92.6 million. The Company intends to use the net 
proceeds from the Offering, together with its existing cash, cash equivalents and marketable securities to advance the 
clinical development of belzupacap sarotalocan for the treatment of choroidal melanoma and choroidal metastasis, to 
develop the platform and for general corporate purposes. The Company believes that the net proceeds from this offering, 
together with its existing cash, cash equivalents and marketable securities, will enable it to fund its operating 
expenses and capital expenditure requirements into the second half of 2026. 
 
Arix holds 1,508,483 shares in Aura. The holding value of these shares will continue to be determined by the market 
price of Aura's shares. 
 
The full text from Aura's announcement can be accessed on the Aura Biosciences website here: https:// 
ir.aurabiosciences.com/press-releases 
 
[ENDS] 
 
Enquiries 
For more information on Arix, please contact: 
 
Arix Bioscience plc 
[phone] 
[e-mail] 
 
Powerscourt Group 
Sarah MacLeod, Ibrahim Khalil, Nick Johnson 
[phone] 
[e-mail] 
 
 
 
About Arix Bioscience plc 
Arix Bioscience plc is a transatlantic venture capital company focused on investing in breakthrough biotechnology 
companies around cutting-edge advances in life sciences. 
 
We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help 
accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this 
exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com 
 
=---------------------------------------------------------------------------------------------------------------------- 
Dissemination of a Regulatory Announcement, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
ISIN:           GB00BD045071 
Category Code:  MSCM 
TIDM:           ARIX 
LEI Code:       213800OVT3AHQCXNIX43 
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State 
Sequence No.:   283959 
EQS News ID:    1770215 
 
End of Announcement  EQS News Service 
=------------------------------------------------------------------------------------
 

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1770215&application_name=news

(END) Dow Jones Newswires

November 10, 2023 03:00 ET (08:00 GMT)